Averica Discovery Expands Capabilities And Capacity By 50%

MARLBOROUGH, MA--(Marketwired - June 02, 2016) -

Averica Discovery Services Inc., an analytical development contract research organization (CRO), today announced new hires and the acquisition of new equipment that significantly expands the Company's capacity and capability. Averica offers analytical development services to pharmaceutical companies; supporting new drug profiling, early to mid-stage clinical development, and CMC.

Averica filled three new laboratory positions, and added new instrument systems: a new preparative Supercritical Fluid Chromatography (SFC) system, mass-directed preparative HPLC systems, and a Charged Aerosol Detector (CAD). The additions enhance the Company's ability to supply early drug development programs while shortening project timelines.

"Averica is growing dramatically," said Jeffery Kiplinger, Ph.D., President of Averica. "Our analytical technologies and scientists are critical to the high quality services we provide. The added preparative chromatography capabilities will offer more capacity for our core services. The new detectors will enable support for new types of client projects, continuing Averica's growth trajectory."

Averica continues to contribute to scientific research, and will present a poster entitled "A Practical Guide to Isolation of the Individual Isomers of Compounds with Three Stereocenters" at the International Symposium on High Performance Liquid Chromatography (HPLC 2016) in San Francisco next month.

About Averica Discovery:
Founded in 2007, Averica Discovery is a Massachusetts-based analytical development contract research organization (CRO) with specialized expertise in small molecule analysis and purification. The company supports chemistry teams by providing material and information required to transition programs from drug discovery to development. With extensive experience in pharmaceutical R&D, it currently offers a variety of chromatography-based services, including method development and qualification, impurity isolation and identification, scalable small molecule purification, and custom assay development. For more information, please visit: www.avericadiscovery.com

Norman Birnbach
Birnbach Communications, Inc.
Email Contact

Back to news